Shares of Manipal Health Enterprises closed at ₹736.55, up 2.08% on the NSE, after the company announced it would use IPO proceeds to retire ₹5,310 crore of non‑convertible debentures. The redemption, executed on June 1, 2026, covered principal, accrued interest and early‑redemption charges, tightening the firm’s leverage to a debt‑to‑EBITDA ratio of 1.8x from 2.4x.
Chief Financial Officer Sameer Agarwal said the transaction "strengthens our balance sheet, cuts interest burden and frees capital for capacity expansion." He added that the move allows the group to invest in technology, talent and new hospital sites while keeping costs under control.
Q1 FY27 data shows revenue up 38.1% YoY to ₹3,091 crore, eclipsing the 12% industry average seen by peers like Apollo and Fortis. Net profit, however, slipped 7.7% to ₹231 crore, down from ₹250 crore a year earlier, while EBITDA rose 25.6% to ₹736.5 crore, though the margin narrowed from 26.2% to 23.8%.
In the broader healthcare segment, Manipal’s revenue growth outpaces the 27% average for the top five Indian hospital chains, but its profit margin compression mirrors a sector‑wide trend of rising operating costs and regulatory capital requirements. Analysts on the NSE have revised their 12‑month target price upward by 4.2% following the debt‑repayment news.
Looking ahead, the company will report FY28 guidance on August 15, where it is expected to maintain a debt‑free stance by June 2027. Investors will be watching whether the freed‑up cash flow translates into new site openings or digital health initiatives, as the CFO hinted at a 10% incremental investment in tech platforms by year‑end.